Analyst firms · BofA Securities · OGN
BofA Securities OGN price target and rating history
Organon & Co. (OGN) · Health Care
BofA Securities rates Organon & Co. (OGN) Underperform with a $25 price target, as of its latest action on Oct 14, 2022. It has published 3 rating actions on OGN since September 2021, including 0 upgrades and 2 downgrades.
- Current rating
- Underperform
- Price target
- $25
- Median target, all firms
- Too few
- Actions on OGN
- 3
BofA Securities price target on OGN
Every BofA Securities rating on OGN
- Oct 14, 2022
- Aug 5, 2022
- Sep 1, 2021
How other firms rate OGN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Piper Sandler | Neutral | $14 | Apr 28, 2026 |
| Barclays | Underweight | $7.50 | Dec 9, 2025 |
Questions about BofA Securities and OGN
- What is BofA Securities's price target for OGN?
- BofA Securities's latest stated price target for Organon & Co. (OGN) is $25, from its action on Oct 14, 2022.
- What is BofA Securities's rating on OGN?
- BofA Securities rates OGN Underperform, a bearish rating, as of Oct 14, 2022.
- When did BofA Securities last change its view on OGN?
- On Oct 14, 2022, BofA Securities downgrades to Underperform from Neutral, price target $27 to $25.
More OGN rating histories
All BofA Securities ratingsOGN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.